Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock Rating Upgraded by B. Riley

Key Points

• B. Riley upgraded Arrowhead Pharmaceuticals (NASDAQ:ARWR) to a "strong-buy" rating, indicating increased confidence in the company's stock.
• A total of five analysts have rated the stock as a buy, with a consensus price target of $43.14, reflecting positive sentiment among market experts.
• Arrowhead's recent earnings report showed a miss in earnings per share at ($1.26), along with revenue of $27.77 million, falling short of analysts' expectations.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) was upgraded by equities research analysts at B. Riley to a "strong-buy" rating in a report issued on Monday,Zacks.com reports.

A number of other research analysts have also issued reports on ARWR. HC Wainwright reaffirmed a "buy" rating and set a $80.00 target price on shares of Arrowhead Pharmaceuticals in a report on Tuesday, May 20th. Royal Bank Of Canada decreased their price target on Arrowhead Pharmaceuticals from $40.00 to $38.00 and set an "outperform" rating for the company in a research report on Friday. TD Cowen upgraded Arrowhead Pharmaceuticals to a "strong-buy" rating in a research report on Monday, July 28th. Citigroup decreased their price target on Arrowhead Pharmaceuticals from $21.00 to $17.00 and set a "neutral" rating for the company in a research report on Tuesday, May 13th. Finally, Chardan Capital reiterated a "buy" rating and issued a $60.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Monday. Three research analysts have rated the stock with a hold rating, five have given a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $43.14.

Arrowhead Pharmaceuticals Stock Performance

Shares of ARWR opened at $17.21 on Monday. The business's fifty day moving average price is $16.50 and its 200 day moving average price is $15.90. Arrowhead Pharmaceuticals has a 12-month low of $9.57 and a 12-month high of $27.34. The stock has a market capitalization of $2.38 billion, a PE ratio of -13.45, a price-to-earnings-growth ratio of 23.70 and a beta of 0.94. The company has a debt-to-equity ratio of 0.39, a current ratio of 4.87 and a quick ratio of 4.87.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last issued its earnings results on Thursday, August 7th. The biotechnology company reported ($1.26) earnings per share for the quarter, missing the consensus estimate of ($0.94) by ($0.32). The business had revenue of $27.77 million during the quarter, compared to analysts' expectations of $29.01 million. During the same quarter in the previous year, the company earned ($1.38) earnings per share. Equities research analysts forecast that Arrowhead Pharmaceuticals will post -2.42 EPS for the current year.

Institutional Trading of Arrowhead Pharmaceuticals

Institutional investors have recently bought and sold shares of the stock. GAMMA Investing LLC raised its holdings in shares of Arrowhead Pharmaceuticals by 297.6% in the first quarter. GAMMA Investing LLC now owns 2,175 shares of the biotechnology company's stock valued at $28,000 after buying an additional 1,628 shares during the last quarter. Nisa Investment Advisors LLC raised its holdings in shares of Arrowhead Pharmaceuticals by 75.9% in the second quarter. Nisa Investment Advisors LLC now owns 3,032 shares of the biotechnology company's stock valued at $48,000 after buying an additional 1,308 shares during the last quarter. GF Fund Management CO. LTD. bought a new stake in Arrowhead Pharmaceuticals during the 4th quarter worth about $49,000. CWM LLC raised its holdings in Arrowhead Pharmaceuticals by 134.3% during the 1st quarter. CWM LLC now owns 4,401 shares of the biotechnology company's stock worth $56,000 after purchasing an additional 2,523 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. raised its holdings in Arrowhead Pharmaceuticals by 29.5% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,335 shares of the biotechnology company's stock worth $84,000 after purchasing an additional 1,214 shares during the last quarter. Institutional investors and hedge funds own 62.61% of the company's stock.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.